Sugi Predict

Sugi Predict / Compounds / SCHEMBL248140

SCHEMBL248140

SCHEMBL248140

OB(O)c1ccc(OC(F)F)nc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DAO P14920 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.35
▸ PIK3CD O00329 1/20 0.32
▸ PIK3CA P42336 1/20 0.32
▸ PIK3CB P42338 1/20 0.32
▸ ENPP2 Q13822 4/20 0.31
▸ CA2 P00918 3/20 0.31
▸ CA1 P00915 2/20 0.31
▸ MGLL Q99685 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ PTGES O14684 3/20 0.31
▸ PDE4A P27815 1/20 0.31
▸ PDE4B Q07343 1/20 0.31
▸ PDE4C Q08493 1/20 0.31
▸ PDE4D Q08499 1/20 0.31
▸ TSHR P16473 1/20 0.30
▸ LPL P06858 1/20 0.30
▸ LIPG Q9Y5X9 1/20 0.30
▸ ACACB O00763 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30525517 1.00 DAO (0.37) DAOKDM4EPIK3CDPIK3CAPIK3CB
SCHEMBL3402397 0.86 — —
SCHEMBL29636288 0.81 ALDH1A1 (0.45) PIK3CDPIK3CAPIK3CBACACB
SCHEMBL561514 0.81 ALDH1A1 (0.45) PIK3CDPIK3CAPIK3CBACACB
SCHEMBL17646787 0.76 LPL (0.32) ENPP2CA2CA1LPLLIPG
SCHEMBL30945175 0.75 DAO (0.39) DAOKDM4EPIK3CDPIK3CAPIK3CB
SCHEMBL29643889 0.75 ENPP2 (0.48) KDM4EENPP2CA2CA1NPC1
SCHEMBL2645473 0.75 DAO (0.39) DAOKDM4EPIK3CDPIK3CAPIK3CB
SCHEMBL4942 0.75 ENPP2 (0.48) KDM4EENPP2CA2CA1NPC1
SCHEMBL3693742 0.74 MGLL (0.39) ENPP2CA2CA1MGLLTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4594318-A1 AKT1 MODULATORS Alterome Therapeutics, Inc. (US) 2025-08-06 — — EP disclosed
US-20250092040-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2025-03-20 — — US disclosed
WO-2025011533-A1 CARBOXYLIC ACID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海宇道生物技术有限公司 2025-01-16 — — WO disclosed
US-20240239797-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-11999730-B1 AKT1 modulators ALTEROME THERAPEUTICS, INC. (US) 2024-06-04 — — US disclosed
US-20240174667-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-05-30 — — US disclosed
WO-2024073371-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2024-04-04 — — WO disclosed
US-20240025879-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2024-01-25 — — US disclosed
US-20240025879-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2024-01-25 — — US disclosed
US-11873290-B2 — — 2024-01-16 — — US disclosed
WO-2022078403-A1 SUBSTITUTED PYRIDONE COMPOUND AND APPLICATION 江苏先声药业有限公司 2022-04-21 — — WO disclosed
WO-2021231615-A1 SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. (US) 2021-11-18 — — WO disclosed
US-11091464-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2021-08-17 — — US disclosed
US-20210188814-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2021-06-24 — — US disclosed
EP-2588471-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY Amgen Inc. (US) 2013-05-08 — — EP disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 — — US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 — — US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 — — US disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 — — WO disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239797-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 DAO 4684/4885KDM4E 2376/4885PIK3CD 9/4885
US-20210188814-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A DAO 1938/4885KDM4E 3514/4885PIK3CD 2288/4885
US-11873290-B2 — IL6, MUSK, IL6ST DAO 2236/4885KDM4E 3221/4885PIK3CD 2434/4885
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 DAO 2334/4885KDM4E 1436/4885PIK3CD 24/4885
US-20250092040-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 DAO 4684/4885KDM4E 2376/4885PIK3CD 9/4885
US-11999730-B1 AKT1 modulators AKT1S1, AKT1, AKT2 DAO 4684/4885KDM4E 2376/4885PIK3CD 9/4885
US-11091464-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A DAO 1938/4885KDM4E 3514/4885PIK3CD 2288/4885
US-20240025879-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A DAO 1938/4885KDM4E 3514/4885PIK3CD 2288/4885
US-20240174667-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 DAO 4684/4885KDM4E 2376/4885PIK3CD 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.